The estimated Net Worth of Ferreira Juan Camilo Arjona is at least $10.2 Million dollars as of 18 January 2023. Juan Arjona owns over 1,109 units of Myovant Sciences Ltd stock worth over $6,655,534 and over the last 7 years he sold MYOV stock worth over $1,592,746. In addition, he makes $1,978,590 as Chief Commercial Officer - Myovant Sciences und Inc at Myovant Sciences Ltd.
Juan has made over 35 trades of the Myovant Sciences Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,109 units of MYOV stock worth $29,821 on 18 January 2023.
The largest trade he's ever made was selling 22,978 units of Myovant Sciences Ltd stock on 27 August 2021 worth over $549,864. On average, Juan trades about 4,236 units every 33 days since 2017. As of 18 January 2023 he still owns at least 246,684 units of Myovant Sciences Ltd stock.
You can see the complete history of Juan Arjona stock trades at the bottom of the page.
Dr. Juan Camilo Arjona Ferreira M.D. serves as Chief Commercial Officer - Myovant Sciences, Inc of the Company. Dr. Arjona Ferreira has served as Chief Medical Officer of Myovant Sciences, Inc. since July 2017. From March 2014 to July 2017, Dr. Arjona Ferreira was Senior Vice President, Clinical Development at Shionogi Inc., a pharmaceutical company, where he served on its U.S. Senior Leadership Team and the Global Scientific Committee and was responsible for leading its U.S. Clinical Development organization. From July 2002 to March 2014, Dr. Arjona Ferreira worked at Merck & Co., Inc., a pharmaceutical company, where he held positions of increased responsibility, the last being Executive Director of Clinical Research in Women’s Health and led the product development teams for all programs in contraception and women’s health. He received his M.D. and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.
As the Chief Commercial Officer - Myovant Sciences und Inc of Myovant Sciences Ltd, the total compensation of Juan Ferreira at Myovant Sciences Ltd is $1,978,590. There are 3 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.
Juan Ferreira is 50, he's been the Chief Commercial Officer - Myovant Sciences und Inc of Myovant Sciences Ltd since 2017. There are 11 older and 2 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.
Ferreira's mailing address filed with the SEC is C/O MYOVANT SCIENCES, INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE, CA, 94005.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... und Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: